Manufacturer of Controlled Substances; Notice of Application, 64298 [E6-18375]
Download as PDF
<![CDATA[
64298
Federal Register / Vol. 71, No. 211 / Wednesday, November 1, 2006 / Notices
Any questions may be directed to the
Joint Board’s Executive Director at 202–
622–8229.
The deadline for accepting
applications is December 15, 2006.
Dated: October 11, 2006.
Patrick W. McDonough,
Executive Director, Joint Board for the
Enrollment of Actuaries.
[FR Doc. 06–8992 Filed 10–31–06; 8:45 am]
BILLING CODE 4830–01–P
DEPARTMENT OF JUSTICE
Deputy Assistant Administrator, Office
of Diversion Control, Drug Enforcement
Administration, that the requirements
for such registration pursuant to 21
U.S.C. 958(a), 21 U.S.C. 823(a), and 21
CFR 1301.34(b), (c), (d), (e), and (f) are
satisfied.
Dated: October 25, 2006.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E6–18431 Filed 10–31–06; 8:45 am]
Dated: October 25, 2006.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E6–18376 Filed 10–31–06; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Application
BILLING CODE 4410–09–P
Drug Enforcement Administration
sroberts on PROD1PC70 with NOTICES
Importer of Controlled Substances;
Notice of Application
DEPARTMENT OF JUSTICE
Prior to issuing a registration under 21
U.S.C. 952(a)(2)(B), and in accordance
with 21 CFR 1301.34(a), this is notice
that on July 25, 2006, Alcan PackagingBethlehem, 2400 Baglyos Circle,
Bethlehem, Pennsylvania, 18020, has
made application to the Drug
Enforcement Administration (DEA) to
be registered as an importer of Nabilone
(7379), a basic class of controlled
substance listed in schedule II.
The company plans to import the
listed controlled substance for
packaging and for distribution.
Any manufacturer who is presently,
or is applying to be, registered with DEA
to manufacture such basic class of
controlled substance may file comments
or objections to the issuance of the
proposed registration and may, at the
same time, file a written request for a
hearing on such application pursuant to
21 CFR 1301.43 and in such form as
prescribed by 21 CFR 1316.47.
Any such written comments or
objections being sent via regular mail
should be addressed, in quintuplicate,
to the Deputy Assistant Administrator,
Office of Diversion Control, Drug
Enforcement Administration,
Washington, DC 20537, Attention: DEA
Federal Register Representative/ODL; or
any being sent via express mail should
be sent to DEA Headquarters, Attention:
DEA Federal Register Representative/
ODL, 2401 Jefferson-Davis Highway,
Alexandria, Virginia 22301; and must be
filed no later than December 1, 2006.
This procedure is to be conducted
simultaneously with and independent
of the procedures described in 21 CFR
1301.34(b), (c), (d), (e), and (f). As noted
in a previous notice published in the
Federal Register on September 23, 1975,
(40 FR 43745–46), all applicants for
registration to import a basic class of
any controlled substance listed in
schedule I or II are, and will continue
to be, required to demonstrate to the
VerDate Aug<31>2005
17:36 Oct 31, 2006
Jkt 211001
Drug Enforcement Administration
Importer of Controlled Substances;
Notice of Registration
By notice dated July 25, 2006, and
published in the Federal Register on
July 31, 2006, (71 FR 43210), Aptuit,
10245 Hickman Mills Drive, Kansas
City, Missouri 64137, made application
by letter to the Drug Enforcement
Administration (DEA) to be registered as
an importer of Marihuana (7360), a basic
class of controlled substance listed in
schedule I.
The company plans to import a
finished pharmaceutical product
containing cannabis extracts in dosage
form for packaging for a clinical trial
study.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and 952(a)
and determined that the registration of
Aptuit to import the basic class of
controlled substance is consistent with
the public interest and with United
States obligations under international
treaties, conventions, or protocols in
effect on May 1, 1971, at this time. DEA
has investigated Aptuit to ensure that
the company’s registration is consistent
with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with state and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 952(a)
and 958(a), and in accordance with 21
CFR 1301.34, the above named company
is granted registration as an importer of
the basic class of controlled substance
listed
PO 00000
Frm 00062
Fmt 4703
Sfmt 4703
Pursuant to § 1301.33(a) of Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on August 28, 2006,
Cambrex Charles City, Inc., 1205 11th
Street, Charles City, Iowa 50616, made
application by letter to the Drug
Enforcement Administration (DEA) to
be registered as a bulk manufacturer of
Sufentanil (9740), a basic class of
controlled substance listed in schedule
II.
The company plans to manufacture
the listed controlled substance in bulk
for distribution to its customers.
Any other such applicant and any
person who is presently registered with
DEA to manufacture such a substance
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections being sent via regular mail
should be addressed, in quintuplicate,
to the Deputy Assistant Administrator,
Office of Diversion Control, Drug
Enforcement Administration,
Washington, DC 20537, Attention: DEA
Federal Register Representative/ODL; or
any being sent via express mail should
be sent to DEA Headquarters, Attention:
DEA Federal Register Representative/
ODL, 2401 Jefferson-Davis Highway,
Alexandria, Virginia 22301; and must be
filed no later than January 2, 2007.
Dated: October 25, 2006.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E6–18375 Filed 10–31–06; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances;
Notice of Registration
By notice dated July 26, 2006, and
published in the Federal Register on
August 1, 2006, (71 FR 43526), Kenco
VPI, Division of Kenco Group Inc., 350
E:\FR\FM\01NON1.SGM
01NON1
]]>Agencies
[Federal Register Volume 71, Number 211 (Wednesday, November 1, 2006)]
[Notices]
[Page 64298]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E6-18375]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled Substances; Notice of Application
Pursuant to Sec. 1301.33(a) of Title 21 of the Code of Federal
Regulations (CFR), this is notice that on August 28, 2006, Cambrex
Charles City, Inc., 1205 11th Street, Charles City, Iowa 50616, made
application by letter to the Drug Enforcement Administration (DEA) to
be registered as a bulk manufacturer of Sufentanil (9740), a basic
class of controlled substance listed in schedule II.
The company plans to manufacture the listed controlled substance in
bulk for distribution to its customers.
Any other such applicant and any person who is presently registered
with DEA to manufacture such a substance may file comments or
objections to the issuance of the proposed registration pursuant to 21
CFR 1301.33(a).
Any such written comments or objections being sent via regular mail
should be addressed, in quintuplicate, to the Deputy Assistant
Administrator, Office of Diversion Control, Drug Enforcement
Administration, Washington, DC 20537, Attention: DEA Federal Register
Representative/ODL; or any being sent via express mail should be sent
to DEA Headquarters, Attention: DEA Federal Register Representative/
ODL, 2401 Jefferson-Davis Highway, Alexandria, Virginia 22301; and must
be filed no later than January 2, 2007.
Dated: October 25, 2006.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. E6-18375 Filed 10-31-06; 8:45 am]
BILLING CODE 4410-09-P
